Outcomes of irinotecan-based chemotherapy regimens in elderly medicare patients with metastatic colorectal cancer

American Journal Geriatric Pharmacotherapy

Volumn 7, Issue 6, 2009, Pages 343-354

  Obeidat, Nour A ^a   Pradel, Françoise G ^a   Zuckerman, Ilene H ^a   DeLisle, Sylvain ^b   Mullins, C Daniel ^a  

^a UNIVERSITY OF MARYLAND   (United States)

^b BALTIMORE VA MEDICAL CENTER   (United States)

Author keywords

chemotherapy; colorectal cancer; irinotecan; SEER Medicare; survival

Indexed keywords

IRINOTECAN;

AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; DRUG COST; DRUG UTILIZATION; ELDERLY CARE; FEMALE; HEALTH CARE UTILIZATION; HEALTH HAZARD; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; METASTASIS; PRIORITY JOURNAL; SIDE EFFECT; SURVIVAL RATE; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; HUMANS; MEDICARE; NEOPLASM METASTASIS; RETROSPECTIVE STUDIES; SEER PROGRAM; TREATMENT OUTCOME; UNITED STATES;

EID: 74549134805     PISSN: 15435946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjopharm.2009.11.005     Document Type: Article

References (38)

1. Board R.E., and Valle J.W. Metastatic colorectal cancer: Current systemic treatment options. Drugs. 67 (2007) 1851-1867
2. Douillard J.Y., Cunningham D., Roth A.D., et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial [published correction appears in Lancet. 2000;355:1372]. Lancet. 355 (2000) 1041-1047
3. Saltz L.B., Cox J.V., Blanke C., et al., Irinotecan Study Group. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med. 343 (2000) 905-914
4. Goldberg R.M., Sargent D.J., Morton R.F., et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 22 (2004) 23-30
5. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 350 (2004) 2335-2342
6. US Dept of Health & Human Services (HHS). HHS names federal coordinating council for comparative effectiveness research: Recovery act allocates $1.1 billion for comparative effectiveness research. http://www.hhs.gov/news/press/2009pres/03/20090319a.html Accessed March 30, 2009
7. Etheredge L.M. Medicare's future: Cancer care. Health Aff (Millwood). 28 (2009) 148-159
8. Mariotto A.B., Yabroff K.R., Feuer E.J., et al. Projecting the number of patients with colorectal carcinoma by phases of care in the US: 2000-2020. Cancer Causes Control. 17 (2006) 1215-1226
9. US Food and Drug Administration (FDA). Drugs @ FDA. Irinotecan Approved Product Label. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm Accessed January 14, 2009
10. National Cancer Institute, US National Institutes of Health. SEER-Medicare: How the SEER & Medicare data are linked. http://healthservices.cancer.gov/seermedicare/overview/linked.html Accessed August 20, 2006
11. Warren J.L., Klabunde C.N., Schrag D., et al. Overview of the SEER-Medicare data: Content, research applications, and generalizability to the United States elderly population. Med Care. 40 Suppl 8 (2002) IV-3-IV-18
12. National Cancer Institute, US National Institutes of Health. SEER-Medicare: Medicare Enrollment & Claims Data. http://healthservices.cancer.gov/seermedicare/medicare/ Accessed August 20, 2006
13. Dobie S.A., Warren J.L., Matthews B., et al. Survival benefits and trends in use of adjuvant therapy among elderly stage II and III rectal cancer patients in the general population. Cancer. 112 (2008) 789-799
14. Dobie S.A., Baldwin L.M., Dominitz J.A., et al. Completion of therapy by Medicare patients with stage III colon cancer. J Natl Cancer Inst. 98 (2006) 610-619
15. Ayanian J.Z., Zaslavsky A.M., Fuchs C.S., et al. Use of adjuvant chemotherapy and radiation therapy for colorectal cancer in a population-based cohort. J Clin Oncol. 21 (2003) 1293-1300
16. Warren J.L., Harlan L.C., Fahey A., et al. Utility of the SEER-Medicare data to identify chemotherapy use. Med Care. 40 Suppl 8 (2002) IV-55-IV-61
17. Schrag D., Gelfand S.E., Bach P.B., et al. Who gets adjuvant treatment for stage II and III rectal cancer? Insight from surveillance, epidemiology, and end results-Medicare. J Clin Oncol. 19 (2001) 3712-3718
18. Cooper G.S., Yuan Z., Stange K.C., et al. Agreement of Medicare claims and tumor registry data for assessment of cancer-related treatment. Med Care. 38 (2000) 411-421
19. Gross C.P., Smith B.D., Wolf E., and Andersen M. Racial disparities in cancer therapy: Did the gap narrow between 1992 and 2002?. Cancer. 112 (2008) 900-908
20. Temple L.K., Hsieh L., Wong W.D., et al. Use of surgery among elderly patients with stage IV colorectal cancer. J Clin Oncol. 22 (2004) 3475-3484
21. Cook A.D., Single R., and McCahill L.E. Surgical resection of primary tumors in patients who present with stage IV colorectal cancer: An analysis of surveillance, epidemiology, and end results data, 1988 to 2000. Ann Surg Oncol. 12 (2005) 637-645
22. Cummings L.C., Payes J.D., and Cooper G.S. Survival after hepatic resection in metastatic colorectal cancer: A populationbased study. Cancer. 109 (2007) 718-726
23. National Cancer Institute, US National Institutes of Health. SEER-Medicare: Identification of diagnosis & procedure codes. http://healthservices.cancer.gov/seermedicare/considerations/identification.html Accessed July 15, 2007
24. Cooper G.S., Virnig B., Klabunde C.N., et al. Use of SEER-Medicare data for measuring cancer surgery. Med Care. 40 Suppl 8 (2002) IV-43-IV-48
25. Delea T.E., Vera-Llonch M., Edelsberg J.S., et al. The incidence and cost of hospitalization for 5-FU toxicity among Medicare beneficiaries with metastatic colorectal cancer. Value Health. 5 (2002) 35-43
26. Du X.L., Chan W., Giordano S., et al. Variation in modes of chemotherapy administration for breast carcinoma and association with hospitalization for chemotherapy-related toxicity. Cancer. 104 (2005) 913-924
27. Klabunde C.N., Legler J.M., Warren J.L., et al. A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. Ann Epidemiol. 17 (2007) 584-590
28. Romano P.S., Roos L.L., and Jollis J.G. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: Differing perspectives. J Clin Epidemiol. 46 (1993) 1075-1079 discussion
29. Romano P.S., Roos L.L., and Jollis J.G. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: Differing perspectives. J Clin Epidemiol. 46 (1993) 1081-1090
30. Baldwin L.M., Klabunde C.N., Green P., et al. In search of the perfect comorbidity measure for use with administrative claims data: Does it exist?. Med Care. 44 (2006) 745-753
31. Charlson M.E., Pompei P., Ales K.L., and MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis. 40 (1987) 373-383
32. National Cancer Institute, US National Institutes of Health. SEER-Medicare: Calculation of comorbidity weights. http://healthservices.cancer.gov/seermedicare/program/comorbidity.html Accessed March 7, 2008
33. Bach P.B., Guadagnoli E., Schrag D., et al. Patient demographic and socioeconomic characteristics in the SEER-Medicare database applications and limitations. Med Care. 40 Suppl 8 (2002) IV-19-IV-25
34. Hershman D., Hall M.J., Wang X., et al. Timing of adjuvant chemotherapy initiation after surgery for stage III colon cancer. Cancer. 107 (2006) 2581-2588
35. Punglia R.S., Weeks J.C., Neville B.A., and Earle C.C. Radiation therapy after mastectomy between 1991 and 1999 in elderly women: Response to clinical trial information. J Clin Oncol. 24 (2006) 3474-3482
36. Zhang X., Loberiza F.R., Klein J.P., and Zhang M.J. A SAS macro for estimation of direct adjusted survival curves based on a stratified Cox regression model [published correction appears in ComputMethods Programs Biomed. 2008;89:313-314]. Comput Methods Programs Biomed. 88 (2007) 95-101
37. Fuchs C.S., Marshall J., Mitchell E., et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Results from the BICC-C Study. J Clin Oncol. 25 (2007) 4779-4786
38. Hoskins J.M., Marcuello E., Altes A., et al. Irinotecan pharmacogenetics: Influence of pharmacodynamic genes. Clin Cancer Res. 14 (2008) 1788-1796